Clinical Trial Details

Trial ID: L0023
Source ID: NCT02029586
Associated Drug: MB12066
Title: Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis
Acronym: --
Status: Terminated
Study Results: No Results Available
Results: --
Conditions: Nonalcoholic Fatty Liver Disease
Interventions: Drug: MB12066 200mg|Drug: Placebo
Outcome Measures: Change in hepatic steatosis(%)|Proportion of subjects with more than 1 point in total NAFLD Activity Score (NAS)|Change in fibrosis score|Change in steatosis score|Change in lobular inflammation score|Change in ballooning score|Change in lipid profile
Sponsor/Collaborators: Yungjin Pharm. Co., Ltd.
Gender: Male
Age: 20 Years and older ?? (Adult, Older Adult)
Phases: Phase 2
Enrollment: 18
Study Type: Interventional
Study Designs: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
Start Date: January 2013
Completion Date: November 2014
Results First Posted: --
Last Update Posted: December 21, 2017
Locations: Seoul St. Mary's Hospital, Seoul, Banpo-daero Seocho-gu, Korea, Republic of|Uijeongbu St. Mary's Hospital, Uijeongbu, Cheonbo-ro Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Daehak-ro Jongno-gu, Korea, Republic of|Keimyung University Donsan Medical Center, Daegu, Dalseong-ro Jung-gu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Dongdeok-ro Jung-gu, Korea, Republic of|Chung-ang University Hospital, Seoul, Heukseok-dong Dongjak-gu, Korea, Republic of|ASAN Medical Center, Seoul, Olympic-ro 43-gil, Songpa-gu, Korea, Republic of|Boramae Hospital, Seoul, Sindaebang-dong Dongjak-gu, Korea, Republic of|Hanyang University Medical Center, Seoul, Wangsimni-ro Seongdong-gu, Korea, Republic of|Severance Hospital, Seoul, Yonsei-ro Seodaemun-gu, Korea, Republic of
URL: https://ClinicalTrials.gov/show/NCT02029586